NovoBind is an integrated animal health company utilizing next-generation biologics to target and neutralize key pathogens affecting producers and food safety. We target pathogens that cause >$1B of production losses and have been materially affected by the following: 1) Antibacterial resistance, 2) A Regulatory ban on antibiotics, and; 3) Changing consumer sentiment.
| Website | https://www.novobind.com/ |
| Employees | 5 (5 on RocketReach) |
| Address | 1021 West Hastings MNP tower, 9th floor, Vancouver, British Columbia V6E 2E9, CA |
| Technologies |
JavaScript
,
HTML
,
Twitter
+11 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology, Science and Engineering |
| Keywords | Animal Health, Pathogens, Biologics, Animal Therapeutics, Protein Therapeutics, Therapeutic Antibodies, Food Safety, Veterinary Medicine, Animal Diseases, Vaccine Development, Antimicrobial, Livestock, Biotechnology, Disease Prevention, Agricultural Technology, Animal Welfare, Precision Livestock Farming, Sustainable Agriculture |
| Competitors | Dendreon, Amgen, アステラス製薬(株), The Janssen Pharmaceutical Companies of Johnson & Johnson, Celltrion Healthcare Co.,Ltd., Celerion, Bristol Myers Squibb, Sorrento Therapeutics, Inc., Regeneron, Roche +43 more (view full list) |
Looking for a particular NovoBind employee's phone or email?
Hamlet Abnousi is the Co-Founder and CEO of NovoBind.
5 people are employed at NovoBind.
NovoBind is based in Vancouver, British Columbia.